Zieg personal page - To The Moon

Zieg

Zieg

No personal profile

1Follow

0Followers

0Topic

0Badge

2023-04-14

[Happy]

2 Nasdaq Growth Stocks That Are Screaming Buys in April

06-21

Great article, would you like to share it?

@quixzi:$Alibaba(BABA)$ Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI

2023-10-30

Great ariticle, would you like to share it?

@Tiger_Academy:Day48. Financial term | Hedge funds

2023-10-30

Great ariticle, would you like to share it?

@Brian Tycangco 鄭彥渊:Demand for APPLE's new flagship smartphone remains weaker than expected

2023-04-14

Great ariticle, would you like to share it?

@ETF Tracker:ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus

2023-04-14

Great ariticle, would you like to share it?

@ETF Tracker:ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3577783292727336","uuid":"3577783292727336","gmtCreate":1614690072220,"gmtModify":1704447506588,"name":"Zieg","pinyin":"zieg","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.08","exceedPercentage":"60.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":319028730486904,"gmtCreate":1718901307464,"gmtModify":1718901311219,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319028730486904","repostId":"318929434230832","repostType":1,"repost":{"id":318929434230832,"gmtCreate":1718873107057,"gmtModify":1718873891097,"author":{"id":"9000000000000615","authorId":"9000000000000615","name":"quixzi","avatar":"https://static.tigerbbs.com/256ffdc976dab81f8d06c84c0e0e8e43","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000615","authorIdStr":"9000000000000615"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> <v-v data-views=\"1\"></v-v>Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","listText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> <v-v data-views=\"1\"></v-v>Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","text":"$Alibaba(BABA)$ Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","images":[{"img":"https://community-static.tradeup.com/news/e22ef4af4dd246f945b5fb4a6ed7ada9","width":"360","height":"270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/318929434230832","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":236110894219456,"gmtCreate":1698676957049,"gmtModify":1698676960169,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236110894219456","repostId":"236035990999192","repostType":1,"repost":{"id":236035990999192,"gmtCreate":1698658248265,"gmtModify":1703746842615,"author":{"id":"4104455119105420","authorId":"4104455119105420","name":"Tiger_Academy","avatar":"https://static.tigerbbs.com/3776fe550cd7a945e43d68c025988ed8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104455119105420","authorIdStr":"4104455119105420"},"themes":[],"title":"Day48. Financial term | Hedge funds","htmlText":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","listText":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","text":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","images":[{"img":"https://community-static.tradeup.com/news/223931197c4ad35aa20434d183b26d8a","width":"1920","height":"1080"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236035990999192","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":236110776582352,"gmtCreate":1698676932096,"gmtModify":1698677048009,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236110776582352","repostId":"236009682337944","repostType":1,"repost":{"id":236009682337944,"gmtCreate":1698651825253,"gmtModify":1698651832802,"author":{"id":"4123627619499482","authorId":"4123627619499482","name":"Brian Tycangco 鄭彥渊","avatar":"https://community-static.tradeup.com/news/7a7bf02c1cfa7da866e95717946e62bc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4123627619499482","authorIdStr":"4123627619499482"},"themes":[],"title":"Demand for APPLE's new flagship smartphone remains weaker than expected","htmlText":"News: <a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>'s Apple <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> 's #iPhone15 prices deeper than those in <a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","listText":"News: <a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>'s Apple <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> 's #iPhone15 prices deeper than those in <a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","text":"News: $JD.com(JD)$'s Apple $Apple(AAPL)$ franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut $Apple(AAPL)$ 's #iPhone15 prices deeper than those in $Alibaba(BABA)$ 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","images":[{"img":"https://community-static.tradeup.com/news/df563c7a29ed29d2d485db91ad3cbb6f","width":"640","height":"394"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236009682337944","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9945151163,"gmtCreate":1681404408653,"gmtModify":1681405675291,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945151163","repostId":"2327623153","repostType":2,"repost":{"id":"2327623153","pubTimestamp":1681397217,"share":"https://ttm.financial/m/news/2327623153?lang=&edition=fundamental","pubTime":"2023-04-13 22:46","market":"us","language":"en","title":"2 Nasdaq Growth Stocks That Are Screaming Buys in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2327623153","media":"Motley Fool","summary":"Massive drivers of fresh earnings are drawing closer, and risks are declining.","content":"<html><head></head><body><p>Among the growth-heavy stocks of the <strong>Nasdaq Composite</strong>, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- <strong>Vertex Pharmaceuticals </strong>(VRTX) and <strong>CRISPR Therapeutics</strong> (CRSP) -- are particularly appealing. That&#39;s thanks to their combination of relative security and near-term catalysts.</p><p>What&#39;s more, their fates are intertwined, so an investment in one could benefit from the positive developments of the other. Here&#39;s why it&#39;s worth buying at least one of the pair.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5b91dbbd7aa3f44290c5cb8cae0dbf2\" tg-width=\"700\" tg-height=\"466\"/></p><p>Image source: Getty Images.</p><h2>1. Vertex Pharmaceuticals</h2><p>Vertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.</p><p>If you&#39;re not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies. Sales of its four medicines for CF led to net income of more than $3.2 billion in 2022. Given that CF is a rare genetic pulmonary disease that only affects 88,000 people in the Western world, and that the company already treats all but around 25,000 of them, its mastery of the market is hard to overstate.</p><p>It&#39;s reasonable to expect its CF business to continue yielding significant income for the foreseeable future as the people living with CF will continue to need its medicines. And soon, if all goes well, it&#39;s set to advance into two markets outside CF for the first time, which should pave the way for further top- and bottom-line growth.</p><p>In collaboration with CRISPR, Vertex announced on April 3 that it had submitted its regulatory approval packet to the Food and Drug Administration (FDA) for its gene therapy, called exa-cel, which is designed to treat a pair of rare genetic diseases called beta thalassemia and sickle cell disease (SCD). If regulators find the application to meets their standards, they could approve the drug in as few as eight months. </p><p>The market for SCD medicines is expected to reach $8.7 billion by 2029, according to Fortune Business Insights, and the market for beta thalassemia therapies could be as large as $823 million by 2030 per a report by Spherical Insights. Capturing a share of both of those markets with exa-cel would position Vertex to potentially grow its 2022 revenue of $8.9 billion significantly more by the end of the decade. And that&#39;s before taking the prospects of sales from any of its other late-stage pipeline programs into account.</p><p>Of course, there&#39;s always the chance of failure in securing approvals and running clinical trials. But given Vertex&#39;s dominance in the CF market, this de-risks the potential consequences of falling short by providing a strong base of revenue -- making this a good time to buy the stock now.</p><h2>2. CRISPR Therapeutics</h2><p>CRISPR Therapeutics stands to benefit even more than Vertex does from getting exa-cel approved, assuming that happens. </p><p>Unlike Vertex, CRISPR doesn&#39;t have any products on the market, which means that exa-cel will be its first chance to generate revenue. Wall Street analysts are guesstimating that if exa-cel gets the go-ahead from the FDA, the company could bring in $297 million in 2024. That would be an enormous rate of revenue growth, to say the least. More importantly, it should position the biotech to self-fund its further pipeline development without the help of debt or collaborators like Vertex. </p><p>On that note, CRISPR has a trio of clinical-stage oncology programs that could ultimately treat lymphoma, among other cancers. It&#39;s also working on a pair of clinical-stage gene therapies to treat diabetes. There&#39;s no guarantee it&#39;ll get any of those programs out the door, even if it wins with exa-cel. The point for investors to appreciate is that in early 2024 it could become self-sustaining, which will dramatically increase its stock&#39;s price. </p><p>Typically, biotech stocks like CRISPR would be quite risky even when they&#39;re likely to commercialize a new medicine. But with more than $1.8 billion in cash and equivalents on hand, and 2022 operating expenses of only $563 million, even a setback with exa-cel shouldn&#39;t bring CRISPR down by much. And if it succeeds, it&#39;ll be adding to its cash hoard -- giving it greater room to maneuver and potentially even acquire promising smaller competitors. And that&#39;s just one more reason it&#39;s an outstanding buy.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Nasdaq Growth Stocks That Are Screaming Buys in April</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Nasdaq Growth Stocks That Are Screaming Buys in April\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Among the growth-heavy stocks of the Nasdaq Composite, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (VRTX) and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRSP":"CRISPR Therapeutics AG","VERX":"Vertex, Inc.","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4139":"生物科技","BK4588":"碎股","BK4023":"应用软件","BK4093":"化肥与农用药剂"},"source_url":"https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2327623153","content_text":"Among the growth-heavy stocks of the Nasdaq Composite, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) -- are particularly appealing. That's thanks to their combination of relative security and near-term catalysts.What's more, their fates are intertwined, so an investment in one could benefit from the positive developments of the other. Here's why it's worth buying at least one of the pair.Image source: Getty Images.1. Vertex PharmaceuticalsVertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.If you're not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies. Sales of its four medicines for CF led to net income of more than $3.2 billion in 2022. Given that CF is a rare genetic pulmonary disease that only affects 88,000 people in the Western world, and that the company already treats all but around 25,000 of them, its mastery of the market is hard to overstate.It's reasonable to expect its CF business to continue yielding significant income for the foreseeable future as the people living with CF will continue to need its medicines. And soon, if all goes well, it's set to advance into two markets outside CF for the first time, which should pave the way for further top- and bottom-line growth.In collaboration with CRISPR, Vertex announced on April 3 that it had submitted its regulatory approval packet to the Food and Drug Administration (FDA) for its gene therapy, called exa-cel, which is designed to treat a pair of rare genetic diseases called beta thalassemia and sickle cell disease (SCD). If regulators find the application to meets their standards, they could approve the drug in as few as eight months. The market for SCD medicines is expected to reach $8.7 billion by 2029, according to Fortune Business Insights, and the market for beta thalassemia therapies could be as large as $823 million by 2030 per a report by Spherical Insights. Capturing a share of both of those markets with exa-cel would position Vertex to potentially grow its 2022 revenue of $8.9 billion significantly more by the end of the decade. And that's before taking the prospects of sales from any of its other late-stage pipeline programs into account.Of course, there's always the chance of failure in securing approvals and running clinical trials. But given Vertex's dominance in the CF market, this de-risks the potential consequences of falling short by providing a strong base of revenue -- making this a good time to buy the stock now.2. CRISPR TherapeuticsCRISPR Therapeutics stands to benefit even more than Vertex does from getting exa-cel approved, assuming that happens. Unlike Vertex, CRISPR doesn't have any products on the market, which means that exa-cel will be its first chance to generate revenue. Wall Street analysts are guesstimating that if exa-cel gets the go-ahead from the FDA, the company could bring in $297 million in 2024. That would be an enormous rate of revenue growth, to say the least. More importantly, it should position the biotech to self-fund its further pipeline development without the help of debt or collaborators like Vertex. On that note, CRISPR has a trio of clinical-stage oncology programs that could ultimately treat lymphoma, among other cancers. It's also working on a pair of clinical-stage gene therapies to treat diabetes. There's no guarantee it'll get any of those programs out the door, even if it wins with exa-cel. The point for investors to appreciate is that in early 2024 it could become self-sustaining, which will dramatically increase its stock's price. Typically, biotech stocks like CRISPR would be quite risky even when they're likely to commercialize a new medicine. But with more than $1.8 billion in cash and equivalents on hand, and 2022 operating expenses of only $563 million, even a setback with exa-cel shouldn't bring CRISPR down by much. And if it succeeds, it'll be adding to its cash hoard -- giving it greater room to maneuver and potentially even acquire promising smaller competitors. And that's just one more reason it's an outstanding buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9945159803,"gmtCreate":1681404287702,"gmtModify":1681405666275,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945159803","repostId":"9942447569","repostType":1,"repost":{"id":9942447569,"gmtCreate":1681293139752,"gmtModify":1681293164938,"author":{"id":"3527667646990931","authorId":"3527667646990931","name":"ETF Tracker","avatar":"https://community-static.tradeup.com/news/087e050021c7db2ae39b1cb7515b694d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667646990931","authorIdStr":"3527667646990931"},"themes":[],"title":"ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus","htmlText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","listText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","text":"Abstract: Companies on the $S&P 500(.SPX)$ are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the $S&P 500(.SPX)$ are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","images":[{"img":"https://community-static.tradeup.com/news/26956ee368668b1a1441558d0e39f197","width":"1407","height":"1849"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9942447569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9945150754,"gmtCreate":1681404207678,"gmtModify":1681405659045,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945150754","repostId":"9942447569","repostType":1,"repost":{"id":9942447569,"gmtCreate":1681293139752,"gmtModify":1681293164938,"author":{"id":"3527667646990931","authorId":"3527667646990931","name":"ETF Tracker","avatar":"https://community-static.tradeup.com/news/087e050021c7db2ae39b1cb7515b694d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667646990931","authorIdStr":"3527667646990931"},"themes":[],"title":"ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus","htmlText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","listText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","text":"Abstract: Companies on the $S&P 500(.SPX)$ are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the $S&P 500(.SPX)$ are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","images":[{"img":"https://community-static.tradeup.com/news/26956ee368668b1a1441558d0e39f197","width":"1407","height":"1849"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9942447569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9945151163,"gmtCreate":1681404408653,"gmtModify":1681405675291,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945151163","repostId":"2327623153","repostType":2,"repost":{"id":"2327623153","pubTimestamp":1681397217,"share":"https://ttm.financial/m/news/2327623153?lang=&edition=fundamental","pubTime":"2023-04-13 22:46","market":"us","language":"en","title":"2 Nasdaq Growth Stocks That Are Screaming Buys in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2327623153","media":"Motley Fool","summary":"Massive drivers of fresh earnings are drawing closer, and risks are declining.","content":"<html><head></head><body><p>Among the growth-heavy stocks of the <strong>Nasdaq Composite</strong>, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- <strong>Vertex Pharmaceuticals </strong>(VRTX) and <strong>CRISPR Therapeutics</strong> (CRSP) -- are particularly appealing. That&#39;s thanks to their combination of relative security and near-term catalysts.</p><p>What&#39;s more, their fates are intertwined, so an investment in one could benefit from the positive developments of the other. Here&#39;s why it&#39;s worth buying at least one of the pair.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5b91dbbd7aa3f44290c5cb8cae0dbf2\" tg-width=\"700\" tg-height=\"466\"/></p><p>Image source: Getty Images.</p><h2>1. Vertex Pharmaceuticals</h2><p>Vertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.</p><p>If you&#39;re not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies. Sales of its four medicines for CF led to net income of more than $3.2 billion in 2022. Given that CF is a rare genetic pulmonary disease that only affects 88,000 people in the Western world, and that the company already treats all but around 25,000 of them, its mastery of the market is hard to overstate.</p><p>It&#39;s reasonable to expect its CF business to continue yielding significant income for the foreseeable future as the people living with CF will continue to need its medicines. And soon, if all goes well, it&#39;s set to advance into two markets outside CF for the first time, which should pave the way for further top- and bottom-line growth.</p><p>In collaboration with CRISPR, Vertex announced on April 3 that it had submitted its regulatory approval packet to the Food and Drug Administration (FDA) for its gene therapy, called exa-cel, which is designed to treat a pair of rare genetic diseases called beta thalassemia and sickle cell disease (SCD). If regulators find the application to meets their standards, they could approve the drug in as few as eight months. </p><p>The market for SCD medicines is expected to reach $8.7 billion by 2029, according to Fortune Business Insights, and the market for beta thalassemia therapies could be as large as $823 million by 2030 per a report by Spherical Insights. Capturing a share of both of those markets with exa-cel would position Vertex to potentially grow its 2022 revenue of $8.9 billion significantly more by the end of the decade. And that&#39;s before taking the prospects of sales from any of its other late-stage pipeline programs into account.</p><p>Of course, there&#39;s always the chance of failure in securing approvals and running clinical trials. But given Vertex&#39;s dominance in the CF market, this de-risks the potential consequences of falling short by providing a strong base of revenue -- making this a good time to buy the stock now.</p><h2>2. CRISPR Therapeutics</h2><p>CRISPR Therapeutics stands to benefit even more than Vertex does from getting exa-cel approved, assuming that happens. </p><p>Unlike Vertex, CRISPR doesn&#39;t have any products on the market, which means that exa-cel will be its first chance to generate revenue. Wall Street analysts are guesstimating that if exa-cel gets the go-ahead from the FDA, the company could bring in $297 million in 2024. That would be an enormous rate of revenue growth, to say the least. More importantly, it should position the biotech to self-fund its further pipeline development without the help of debt or collaborators like Vertex. </p><p>On that note, CRISPR has a trio of clinical-stage oncology programs that could ultimately treat lymphoma, among other cancers. It&#39;s also working on a pair of clinical-stage gene therapies to treat diabetes. There&#39;s no guarantee it&#39;ll get any of those programs out the door, even if it wins with exa-cel. The point for investors to appreciate is that in early 2024 it could become self-sustaining, which will dramatically increase its stock&#39;s price. </p><p>Typically, biotech stocks like CRISPR would be quite risky even when they&#39;re likely to commercialize a new medicine. But with more than $1.8 billion in cash and equivalents on hand, and 2022 operating expenses of only $563 million, even a setback with exa-cel shouldn&#39;t bring CRISPR down by much. And if it succeeds, it&#39;ll be adding to its cash hoard -- giving it greater room to maneuver and potentially even acquire promising smaller competitors. And that&#39;s just one more reason it&#39;s an outstanding buy.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Nasdaq Growth Stocks That Are Screaming Buys in April</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Nasdaq Growth Stocks That Are Screaming Buys in April\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Among the growth-heavy stocks of the Nasdaq Composite, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (VRTX) and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRSP":"CRISPR Therapeutics AG","VERX":"Vertex, Inc.","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4139":"生物科技","BK4588":"碎股","BK4023":"应用软件","BK4093":"化肥与农用药剂"},"source_url":"https://www.fool.com/investing/2023/04/13/2-nasdaq-growth-stocks-that-are-screaming-buys-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2327623153","content_text":"Among the growth-heavy stocks of the Nasdaq Composite, a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) -- are particularly appealing. That's thanks to their combination of relative security and near-term catalysts.What's more, their fates are intertwined, so an investment in one could benefit from the positive developments of the other. Here's why it's worth buying at least one of the pair.Image source: Getty Images.1. Vertex PharmaceuticalsVertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.If you're not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies. Sales of its four medicines for CF led to net income of more than $3.2 billion in 2022. Given that CF is a rare genetic pulmonary disease that only affects 88,000 people in the Western world, and that the company already treats all but around 25,000 of them, its mastery of the market is hard to overstate.It's reasonable to expect its CF business to continue yielding significant income for the foreseeable future as the people living with CF will continue to need its medicines. And soon, if all goes well, it's set to advance into two markets outside CF for the first time, which should pave the way for further top- and bottom-line growth.In collaboration with CRISPR, Vertex announced on April 3 that it had submitted its regulatory approval packet to the Food and Drug Administration (FDA) for its gene therapy, called exa-cel, which is designed to treat a pair of rare genetic diseases called beta thalassemia and sickle cell disease (SCD). If regulators find the application to meets their standards, they could approve the drug in as few as eight months. The market for SCD medicines is expected to reach $8.7 billion by 2029, according to Fortune Business Insights, and the market for beta thalassemia therapies could be as large as $823 million by 2030 per a report by Spherical Insights. Capturing a share of both of those markets with exa-cel would position Vertex to potentially grow its 2022 revenue of $8.9 billion significantly more by the end of the decade. And that's before taking the prospects of sales from any of its other late-stage pipeline programs into account.Of course, there's always the chance of failure in securing approvals and running clinical trials. But given Vertex's dominance in the CF market, this de-risks the potential consequences of falling short by providing a strong base of revenue -- making this a good time to buy the stock now.2. CRISPR TherapeuticsCRISPR Therapeutics stands to benefit even more than Vertex does from getting exa-cel approved, assuming that happens. Unlike Vertex, CRISPR doesn't have any products on the market, which means that exa-cel will be its first chance to generate revenue. Wall Street analysts are guesstimating that if exa-cel gets the go-ahead from the FDA, the company could bring in $297 million in 2024. That would be an enormous rate of revenue growth, to say the least. More importantly, it should position the biotech to self-fund its further pipeline development without the help of debt or collaborators like Vertex. On that note, CRISPR has a trio of clinical-stage oncology programs that could ultimately treat lymphoma, among other cancers. It's also working on a pair of clinical-stage gene therapies to treat diabetes. There's no guarantee it'll get any of those programs out the door, even if it wins with exa-cel. The point for investors to appreciate is that in early 2024 it could become self-sustaining, which will dramatically increase its stock's price. Typically, biotech stocks like CRISPR would be quite risky even when they're likely to commercialize a new medicine. But with more than $1.8 billion in cash and equivalents on hand, and 2022 operating expenses of only $563 million, even a setback with exa-cel shouldn't bring CRISPR down by much. And if it succeeds, it'll be adding to its cash hoard -- giving it greater room to maneuver and potentially even acquire promising smaller competitors. And that's just one more reason it's an outstanding buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":319028730486904,"gmtCreate":1718901307464,"gmtModify":1718901311219,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/319028730486904","repostId":"318929434230832","repostType":1,"repost":{"id":318929434230832,"gmtCreate":1718873107057,"gmtModify":1718873891097,"author":{"id":"9000000000000615","authorId":"9000000000000615","name":"quixzi","avatar":"https://static.tigerbbs.com/256ffdc976dab81f8d06c84c0e0e8e43","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000615","authorIdStr":"9000000000000615"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> <v-v data-views=\"1\"></v-v>Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","listText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> <v-v data-views=\"1\"></v-v>Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","text":"$Alibaba(BABA)$ Reason to be Bullish on BABA➛ Talks of Supportive Monetary Policy➛ Falling Wedge Breakout with Golden Cross after GZ➛ CN's Top Market Regulator unveiled fresh measures to improve Nasdaq style Tech Board➛ Measures of New Stimulus + Reverse Repo➛ 618 Shopping Festival, surpassed 26.3 billion yuan, vs 19.4 bln in 2023, setting a new record for large-scale promotional events➛ Seasonality at it's Highest in June➛ Removal of Regulatory Clampdown➛ Development of new Open Source AI","images":[{"img":"https://community-static.tradeup.com/news/e22ef4af4dd246f945b5fb4a6ed7ada9","width":"360","height":"270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/318929434230832","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":236110894219456,"gmtCreate":1698676957049,"gmtModify":1698676960169,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236110894219456","repostId":"236035990999192","repostType":1,"repost":{"id":236035990999192,"gmtCreate":1698658248265,"gmtModify":1703746842615,"author":{"id":"4104455119105420","authorId":"4104455119105420","name":"Tiger_Academy","avatar":"https://static.tigerbbs.com/3776fe550cd7a945e43d68c025988ed8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104455119105420","authorIdStr":"4104455119105420"},"themes":[],"title":"Day48. Financial term | Hedge funds","htmlText":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","listText":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","text":"Hedge funds are specialized investment funds that utilize various investment strategies to help investors manage risks and achieve profits. These funds can invest in a wide range of markets, including stocks, bonds, and commodities, aiming to generate profits not solely dependent on market fluctuations.In simple terms, hedge funds are a unique type of investment fund that employs diversified investment strategies to manage risks and generate returns.Here's an example:Let's consider a hedge fund with an initial capital of $1,000,000. It allocates funds in the following proportions: 40% for the stock market, 30% for the bond market, and 30% for the commodity market.In the stock market, the fund invests $400,000. After one year, the stock investment yields a 20% return, amounting to $80,000.I","images":[{"img":"https://community-static.tradeup.com/news/223931197c4ad35aa20434d183b26d8a","width":"1920","height":"1080"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236035990999192","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":236110776582352,"gmtCreate":1698676932096,"gmtModify":1698677048009,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236110776582352","repostId":"236009682337944","repostType":1,"repost":{"id":236009682337944,"gmtCreate":1698651825253,"gmtModify":1698651832802,"author":{"id":"4123627619499482","authorId":"4123627619499482","name":"Brian Tycangco 鄭彥渊","avatar":"https://community-static.tradeup.com/news/7a7bf02c1cfa7da866e95717946e62bc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4123627619499482","authorIdStr":"4123627619499482"},"themes":[],"title":"Demand for APPLE's new flagship smartphone remains weaker than expected","htmlText":"News: <a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>'s Apple <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> 's #iPhone15 prices deeper than those in <a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","listText":"News: <a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>'s Apple <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut <a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a> 's #iPhone15 prices deeper than those in <a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a> 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","text":"News: $JD.com(JD)$'s Apple $Apple(AAPL)$ franchise store offers higher price cuts in the iPhone 15 series than Tmall during the 'Double Eleven' shopping festival, which is the first cut in one of the official supply channels ever seen.ImageMy comment:JD's stores cut $Apple(AAPL)$ 's #iPhone15 prices deeper than those in $Alibaba(BABA)$ 's TMall. Indicative of weaker-than-expected demand for the new flagship smartphone despite a foreseen recovery in industry sales in 4Q (i.e. Golden Week sales +15% YoY).","images":[{"img":"https://community-static.tradeup.com/news/df563c7a29ed29d2d485db91ad3cbb6f","width":"640","height":"394"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/236009682337944","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9945159803,"gmtCreate":1681404287702,"gmtModify":1681405666275,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945159803","repostId":"9942447569","repostType":1,"repost":{"id":9942447569,"gmtCreate":1681293139752,"gmtModify":1681293164938,"author":{"id":"3527667646990931","authorId":"3527667646990931","name":"ETF Tracker","avatar":"https://community-static.tradeup.com/news/087e050021c7db2ae39b1cb7515b694d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667646990931","authorIdStr":"3527667646990931"},"themes":[],"title":"ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus","htmlText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","listText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","text":"Abstract: Companies on the $S&P 500(.SPX)$ are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the $S&P 500(.SPX)$ are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","images":[{"img":"https://community-static.tradeup.com/news/26956ee368668b1a1441558d0e39f197","width":"1407","height":"1849"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9942447569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9945150754,"gmtCreate":1681404207678,"gmtModify":1681405659045,"author":{"id":"3577783292727336","authorId":"3577783292727336","name":"Zieg","avatar":"https://community-static.tradeup.com/news/b409216d41d9d49e729219cf7c5d8107","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577783292727336","authorIdStr":"3577783292727336"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945150754","repostId":"9942447569","repostType":1,"repost":{"id":9942447569,"gmtCreate":1681293139752,"gmtModify":1681293164938,"author":{"id":"3527667646990931","authorId":"3527667646990931","name":"ETF Tracker","avatar":"https://community-static.tradeup.com/news/087e050021c7db2ae39b1cb7515b694d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667646990931","authorIdStr":"3527667646990931"},"themes":[],"title":"ETF Tracker| Worst Earnings Season! Consumer, Industrial, and Energy ETFs in Focus","htmlText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","listText":"Abstract: Companies on the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the <a href=\"https://ttm.financial/S/.SPX\">$S&amp;P 500(.SPX)$</a> are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","text":"Abstract: Companies on the $S&P 500(.SPX)$ are expected to report their weakest profit growth in nearly three years.This week, the US stock market's earnings season gained much anticipation. Due to factors such as weak performance, technology sector’s return to fundamentals, high risks of financial institution, and increased corporate debt, market participants are generally bearish about the US stocks.Companies of the $S&P 500(.SPX)$ are expected to report a 6.8% decline in earnings per share in the first quarter, the largest drop since the second quarter of 2020.The latest data from FactSet shows that analysts expect earnings to decline 4.6% in the second quarter and then grow again in the thir","images":[{"img":"https://community-static.tradeup.com/news/26956ee368668b1a1441558d0e39f197","width":"1407","height":"1849"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9942447569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}